Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
Xiaofei Li,1 Jia Wan,2 Zhenping Wu,3 Juncai Tu,1 Yongtao Hu,1 Shuang Wu,1 Lianqing Lou1 1Department of Infectious Diseases, Yiwu Central Hospital, Yiwu, China; 2The First Hospital of Nanchang, Nanchang, China; 3Gastroenterology Department, Jinhua Central Hospital, Jinhua, China Aims: Concerns have...
Main Authors: | Li X, Wan J, Wu Z, Tu J, Hu Y, Wu S, Lou L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/fatal-adverse-events-with-molecular-targeted-agents-in-the-treatment-o-peer-reviewed-article-DDDT |
Similar Items
-
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01) -
Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Jiang Y, et al.
Published: (2019-02-01) -
Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
by: Xuewen Wang, et al.
Published: (2020-01-01) -
Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Xiaolin Yu, et al.
Published: (2021-02-01) -
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
by: Shigeo Shimose, et al.
Published: (2020-07-01)